Patents by Inventor James Waring
James Waring has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110049277Abstract: The present invention is generally related to an apparatus having cutter elements for destroying articles such as paper sheets and a mechanism for advancing at least a top sheet from a stack of paper in a tray into the cutter elements for shredding. In one embodiment, the apparatus uses a rotatable feed roller to feed paper atop the stack to the cutter elements. The feed roller moves in an alternating manner between a lowered and raised position to engage and disengage the stack when advancing the paper therethrough. Alternatively, a rotatable cam may be used. In an embodiment, the apparatus uses a rotatable drum or rotatable belt with an internal vacuum to lift paper from the stack and feed into the shredder mechanism.Type: ApplicationFiled: November 8, 2010Publication date: March 3, 2011Applicant: Fellowes Inc.Inventors: Tai Hoon K. MATLIN, Dipan Pravin Surati, Dennis W. Gruber, James Waring
-
Patent number: 7897778Abstract: The invention concerns benzamide compounds of Formula (I), wherein R1a, R1b, R1c, R2, R3, R4, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).Type: GrantFiled: August 31, 2005Date of Patent: March 1, 2011Assignee: AstraZenecaInventors: Keith Hopkinson Gibson, Elaine Sophie Elizabeth Stokes, Michael James Waring, David Michael Andrews, Zbigniew Stanley Matusiak, Mark Andrew Graham
-
Publication number: 20100331329Abstract: The invention concerns a compound of the formula (I) wherein Ring A is heterocyclyl; m is 0-4 and each R1 is a group such as hydroxy, halo, trifluoromethyl and cyano; R2 is halo and n is 0-2; and each R4 is a group such as hydroxy, halo, trifluoromethyl and cyano; p is 0-4; and R3 is amino or hydroxy; or pharmaceutically-acceptable salts or in-vivo-hydrolysable ester or amide thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical condions mediated by histone deacetylase.Type: ApplicationFiled: September 10, 2010Publication date: December 30, 2010Applicant: ASTRAZENECA ABInventors: Elaine Sophie Elizabeth Stokes, Craig Anthony Roberts, Michael James Waring
-
Publication number: 20100320299Abstract: A shredder includes a housing having a throat for receiving articles be shredded and a shredder mechanism. The shredder mechanism includes a motor and cutter elements, and enables the articles to be shredded to be fed into the cutter elements. The motor drives the cutter elements to shred the articles. A cam mechanism is provided in the throat and is movable from a disengaged position to an engaged position responsive to insertion into the throat of articles above a predetermined maximum thickness threshold. In the engaged position, the cam mechanism engages the articles to prevent further insertion thereof into the throat, and in the disengaged position the cam mechanism is disengaged from the articles to permit further insertion thereof into the throat. The cam mechanism may be movable between a closed position and an open position. In the closed position, the cam mechanism is configured to block the throat.Type: ApplicationFiled: June 18, 2009Publication date: December 23, 2010Applicant: Fellowes, Inc.Inventors: Tai Hoon K. Matlin, James Waring
-
Publication number: 20100324068Abstract: DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.Type: ApplicationFiled: June 18, 2010Publication date: December 23, 2010Applicant: AstraZeneca ABInventors: Alan Martin Birch, Roger John Butlin, Leonie Campbell, Clive Green, Andrew Leach, Michael James Waring, Paul Michael Murray, Per Olof Ryberg
-
Publication number: 20100320297Abstract: A shredder including a housing having a throat for receiving articles to be shredded, a shredder mechanism, a blocking member, and an electrically powered motor and cutter elements. A thickness detector comprises a contact member extending into the throat. The shredder includes an actuator for moving the blocking member between a retracted position and an extended position. The actuator and the thickness detector are coupled to enable the actuator to move the blocking member from the retracted position to the extended position responsive to the movement of the contact member by insertion into the throat of the at least one article above a predetermined maximum thickness threshold. The blocking member is configured such that in the extended position the blocking member prevents further insertion of the at least one article into the throat, and in the retracted position the blocking member permits further insertion thereof into the throat.Type: ApplicationFiled: June 17, 2010Publication date: December 23, 2010Applicant: Fellowes, Inc.Inventors: Tai Hoon K. Matlin, James Waring, Dmitry Romanovich, Keeley Michael Kabala
-
Patent number: 7842694Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: GrantFiled: September 3, 2008Date of Patent: November 30, 2010Assignee: AstraZeneca ABInventors: Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20100261704Abstract: A compound (2S)-2-[1-(2,6-dichlorophenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-(3-hydroxyazetidin-1-yl)-N-(5-methylpyrazin-2-yl)propanamide is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: AstraZeneca ABInventor: Michael James WARING
-
Publication number: 20100261733Abstract: (2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.Type: ApplicationFiled: April 8, 2010Publication date: October 14, 2010Applicant: AstraZeneca ABInventors: Stuart Norman Lile Bennett, Rolf Peter Walker, Michael James Waring
-
Publication number: 20100173825Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).Type: ApplicationFiled: December 22, 2009Publication date: July 8, 2010Applicant: AstraZeneca ABInventors: Nathaniel George Martin, Darren Mckerrecher, Kurt Gordon Pike, Michael James Waring
-
Patent number: 7745475Abstract: Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described.Type: GrantFiled: June 1, 2005Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: Craig Johnstone, Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20100093757Abstract: A compound of Formula (I): is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.Type: ApplicationFiled: August 4, 2009Publication date: April 15, 2010Applicant: AstraZeneca ABInventors: Stuart Norman Lile BENNETT, Roger John Butlin, Leonie Campbell, Robert Darren Morse Davies, Graeme Richard Robb, Rolf Peter Walker, Michael James Waring, Helen Claire Pointon, Mikael Dan Brink, Jonas Rickard Fägerhag, Ulrik Jurva, Volker Schnecke, Anette Marie Svensson Henriksson, Christer Ralf Westerlund, Peter Gustaf Bonn
-
Publication number: 20100075942Abstract: The invention concerns benzamide derivatives of Formula (I) wherein R1a, R1b, R1c, R2, R3, R4, W, m and n have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).Type: ApplicationFiled: January 12, 2006Publication date: March 25, 2010Applicant: ASTRAZENECA ABInventors: Keith Hopkinson Gibson, Elaine Sophie, Elizabeth Stokes, Michael James Waring, David Michael Andrews, Zbigniew Stanley Matusiak, Mark Maybury, Craig Anthony Roberts
-
Patent number: 7671060Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).Type: GrantFiled: October 26, 2007Date of Patent: March 2, 2010Assignee: AstraZeneca ABInventors: Nathaniel George Martin, Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Patent number: 7642263Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and prodrugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: GrantFiled: September 2, 2008Date of Patent: January 5, 2010Assignee: AstraZeneca ABInventors: Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Patent number: 7642259Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: GrantFiled: July 3, 2006Date of Patent: January 5, 2010Assignee: AstraZeneca ABInventors: Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20090264336Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: ApplicationFiled: September 3, 2008Publication date: October 22, 2009Applicant: AstraZeneca ABInventors: Darren MCKERRECHER, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20090253676Abstract: Compounds of Formula (I): wherein: R1 is hydroxymethyl; R2 is selected from —C(O)NR4R5, —SO2NR4R5, —S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described.Type: ApplicationFiled: December 16, 2008Publication date: October 8, 2009Applicant: AstraZeneca ABInventors: Craig Johnstone, Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20090118159Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: ApplicationFiled: July 3, 2006Publication date: May 7, 2009Inventors: Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
-
Publication number: 20090111790Abstract: Compounds of formula (I) wherein R1, HET-1 and HET-2 are as described in the specification, and their salts and pro-drugs, are activators of glucokinase (GLK) and are thereby useful in the treatment of, for example, type 2 diabetes. Processes for preparing compounds of formula (I) are also described.Type: ApplicationFiled: October 22, 2008Publication date: April 30, 2009Applicant: AstraZeneca ABInventors: Darren MCKERRECHER, Kurt Gordon Pike, Michael James Waring